New Therapeutic Agents In Thrombosis And Thrombolysis, Revised And Expanded, Second Edition (Fundamental and Clinical Cardiology)
Description
Presents new chapters discussing the latest research on low-molecular-weight heparins, as well as agents such as pentasaccharide, TFP1, soluble thrombomodulin, and alfimeprase.
Completely revised and expanded throughout, New Therapeutic Agents in Thrombosis and Thrombolysis details strategies to
target conventional and recently characterized pathways of hemostasis
minimize the prothrombotic function of activated platelets
assess the biochemical and pharmacological effects of antithrombotic agents
and discusses
the use of animal models for determination of antithrombotic drug efficacy
antithrombotic therapy as a key component of cardiovascular disease management
the management of thromboembolic events in children and pregnant women
Supplemented with more than 2000 contemporary references, New Therapeutic Agents in Thrombosis and Thrombolysis is an authoritative source for cardiologists, internists, primary care physicians, vascular medicine specialists, cardiovascular and vascular surgeons, hematologists, pulmonologists, critical care physicians, pharmacologists, pharmaceutical researchers, and fellows, residents, and graduate and medical school students in these disciplines.
Completely revised and expanded throughout, New Therapeutic Agents in Thrombosis and Thrombolysis details strategies to
and discusses
Supplemented with more than 2000 contemporary references, New Therapeutic Agents in Thrombosis and Thrombolysis is an authoritative source for cardiologists, internists, primary care physicians, vascular medicine specialists, cardiovascular and vascular surgeons, hematologists, pulmonologists, critical care physicians, pharmacologists, pharmaceutical researchers, and fellows, residents, and graduate and medical school students in these disciplines.
